Timm Medical Technologies is a medical device and pharmaceutical company specializing in marketing and sales of men’s health products including STENDRA® (avanafil tablets) and ERECAID® to over 3,000 urology practices in US. Timm Medical Technologies has approximately 32 sales representatives that will promote PREBOOST® to urologists.
As reported in
Timm will target urology practices as well as over the counter (OTC) websites such as www.PREBOOST.com to develop product awareness and to set up distribution of PREBOOST® directly to patients from physicians’ offices.
“Timm Medical is a well-known specialty pharmaceutical company with an impressive marketing and sales record focusing on erectile dysfunction and men’s health. They also have an extensive database of urology medical practitioners and independent distributors who will increase awareness of and patient access to PREBOOST®,” said
“We are excited to partner with
About Premature Ejaculation
The PREBOOST® Clinical Study enrolled 26 men aged 18 years or older in a heterosexual, monogamous relationship, with PE, defined as reported poor control over ejaculation, personal distress related to ejaculation and average IELT of two minutes or less on stopwatch measurement. Subjects were randomized 2:1 to treatment with benzocaine wipes or placebo wipes, with men in the placebo group crossed over to the treatment group one month after randomization. The primary outcome measure for the study was change in IELT at two months, with secondary outcomes including change in questionnaire assessments of global rating of distress, medication assessment and IPE. Data showed that patients treated with benzocaine 4% wipes demonstrated a statistically significant improvement in IELT after the first month of treatment (2.75 minutes), with greater improvement after the second month (5.5 minutes), compared to placebo (1.8 minutes). Men in the treatment group also reported greater improvement in distress relating to intercourse, control of ejaculation and satisfaction with sexual intercourse over the study period. After treatment with PREBOOST®, 82 percent of men were no longer considered to have premature ejaculation. Results showed that treatment was well tolerated. PREBOOST® is available for sale in the U.S. at www.PREBOOST.com.
About Veru Inc.
The company’s division,
More information about
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
Press Release Kari Sharp